Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BARIcitinib Cognitive Emotional and Neural signaTuRE BARICENTRE

Trial Profile

BARIcitinib Cognitive Emotional and Neural signaTuRE BARICENTRE

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms BARICENTRE

Most Recent Events

  • 31 Jan 2024 This study has been completed in France, according to European Clinical Trials Database record.
  • 14 Nov 2023 Status changed from recruiting to discontinued.
  • 22 Aug 2022 Planned End Date changed from 1 Jul 2024 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top